1. bookVolume 4 (2021): Issue 1 (June 2021)
Journal Details
License
Format
Journal
eISSN
2668-5124
First Published
30 Sep 2019
Publication timeframe
2 times per year
Languages
English
access type Open Access

Perspectives on Antiviral Drugs Development in the Treatment of COVID-19

Published Online: 01 Jul 2021
Volume & Issue: Volume 4 (2021) - Issue 1 (June 2021)
Page range: 44 - 59
Received: 01 Jun 2021
Accepted: 11 Jun 2021
Journal Details
License
Format
Journal
eISSN
2668-5124
First Published
30 Sep 2019
Publication timeframe
2 times per year
Languages
English
Abstract

The main objective of this review is to highlight the urgent development of new antiviral drugs against SARS-CoV-2 in the context of the coronavirus pandemic. Antiviral medication against SARS-CoV-2 comprises only remdesivir as an approved drug. Scientists are making considerable efforts to identify other effective antivirals. Investments into the de novo design of new drugs against the SARS-CoV-2 virus are few. Molnupiravir proved to be effective against the SARS-CoV-2 virus and is very close to approval. Pfizer’s two new compounds (PF-07321332, oral administration and PF-07304814, systemic administration) are in the early stages of development. Two types of methods are preferred to discover new antivirals in a short period. Repositioning of approved drugs for antiviral effect conducted to some clinical results for favipiravir, lopinavir/ritonavir, danoprevir/ritonavir, umifenovir, hydroxychloroquine, camostat and nafamostat. Virtual screening of known molecules’ libraries indicated several compounds that were tested or are being tested in clinical trials. In conclusion, only a few innovative antiviral molecules are in various stages of development. However, the repositioning of many known compounds is being studied, including using virtual screening. The pharmaceutical industry is adapting and reinventing itself so that humanity can face a new pandemic in the future.

Keywords

1. Adamson CS, Chibale K, Goss RJM, Jaspars M, Newman DJ, Dorrington RA (2021) Antiviral drug discovery: preparing for the next pandemic. Chem Soc Rev 50:3647–3655. doi: 10.1039/D0CS01118E10.1039/D0CS01118E33524090 Search in Google Scholar

2. Agrawal U, Raju R, Udwadia ZF (2020) Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India 76:370–376. doi: 10.1016/j.mjafi.2020.08.00410.1016/j.mjafi.2020.08.004746706732895599 Search in Google Scholar

3. Akilesh SM, J R, Palanisamy D, Wadhwani A (2021) Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight. Curr Pharm Biotechnol 22:192–199. doi:10.2174/138920102199920082015592710.2174/138920102199920082015592732867651 Search in Google Scholar

4. Amendola G, Ettari R, Previti S, Di Chio C, Messere A, Di Maro S, Hammerschmidt SJ, Zimmer C, Zimmermann RA, Schirmeister T, Zappalà M, Cosconati S (2021) Lead Discovery of SARS-CoV-2 Main Protease Inhibitors through Covalent Docking-Based Virtual Screening. J Chem Inf Model 61:2062–2073. doi: 10.1021/acs.jcim.1c0018410.1021/acs.jcim.1c00184802944733784094 Search in Google Scholar

5. Antiviral Therapy [WWW Document] (Last updated: 11 Feb 2021) COVID-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/ Accessed 20 May 2021 Search in Google Scholar

6. Azam F, Taban IM, Eid EEM, Iqbal M, Alam O, Khan S, Mahmood D, Anwar MJ, Khalilullah H, Khan MU (2020) An insilico analysis of ivermectin interaction with potential SARS-CoV-2 targets and host nuclear importin α. J Biomol Struct Dyn 1–14. doi: 10.1080/07391102.2020.184102810.1080/07391102.2020.1841028764342233131430 Search in Google Scholar

7. Bello M (2021) Elucidation of the inhibitory activity of ivermectin with host nuclear importin α and several SARS-CoV-2 targets. J Biomol Struct Dyn 1–9. doi: 10.1080/07391102.2021.191185710.1080/07391102.2021.1911857805493633843474 Search in Google Scholar

8. Benlloch J-M, Cortés J-C, Martínez-Rodríguez D, Julián R-S, Villanueva R-J (2020) Effect of the early use of antivirals on the COVID-19 pandemic. A computational network modeling approach. Chaos Soliton Fract 140:110168. doi: 10.1016/j.chaos.2020.11016810.1016/j.chaos.2020.110168743436832836917 Search in Google Scholar

9. Bhowmick S, Dang A, Vallish BN, Dang S (2021) Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review. Drug Saf. doi: 10.1007/s40264-021-01066-y10.1007/s40264-021-01066-y805154833864232 Search in Google Scholar

10. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (2020) The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res 178:104787. doi: 10.1016/j.antiviral.2020.10478710.1016/j.antiviral.2020.104787712905932251768 Search in Google Scholar

11. Chen H, Zhang Z, Wang L, Huang Z, Gong F, Li X, Chen Y, Wu JJ (2020) First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients. Medicine (Baltimore) 99. doi: 10.1097/MD.000000000002335710.1097/MD.0000000000023357771019233235105 Search in Google Scholar

12. Choudhury A, Das NC, Patra R, Bhattacharya M, Ghosh P, Patra BC, Mukherjee S (2021) Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach. Future Virol 16:277–291. doi: 10.2217/fvl-2020-034210.2217/fvl-2020-0342 Search in Google Scholar

13. Dabbous HM, El-Sayed MH, El Assal G, Elghazaly H, Ebeid FFS, Sherief AF, Elgaafary M, Fawzy E, Hassany SM, Riad AR, TagelDin MA (2021) Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. Sci Rep-UK 11:7282. doi: 10.1038/s41598-021-85227-010.1038/s41598-021-85227-0 Search in Google Scholar

14. Dolgin E (2021) The race for antiviral drugs to beat COVID — and the next pandemic. Nature 592:340–343. doi: 10.1038/d41586-021-00958-410.1038/d41586-021-00958-4 Search in Google Scholar

15. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD (2020) Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent Sci 6:672–683. doi: 10.1021/acscentsci.0c0048910.1021/acscentsci.0c00489 Search in Google Scholar

16. Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, Cuscó MD-A, Ferrández O, Horcajada JP, Grau S (2021) Azithromycin in the treatment of COVID-19: a review. Expert Rev Anti-infe 19:147–163. doi: 10.1080/14787210.2020.181302410.1080/14787210.2020.1813024 Search in Google Scholar

17. Everts M, n.d. Antiviral Drug Discovery and Development Center | UAB [WWW Document]. https://www.uab.edu/medicine/ad3c/ Accessed 20 May 2021 Search in Google Scholar

18. FDA (2020) Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment [WWW Document]. FDA. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment Accessed 30 Sep 2020 Search in Google Scholar

19. FDA (2021) COVID-19 Vaccines. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines Accessed 21 May 2021 Search in Google Scholar

20. Frediansyah A, Tiwari R, Sharun K, Dhama K, Harapan H (2021) Antivirals for COVID-19: A critical review. Clin Epidemiol Glob Health 9:90–98. doi: 10.1016/j.cegh.2020.07.00610.1016/j.cegh.2020.07.006 Search in Google Scholar

21. Gatti M, De Ponti F (2021) Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. Pharmaceutics 13. doi: 10.3390/pharmaceutics1303030210.3390/pharmaceutics13030302 Search in Google Scholar

22. Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M (2021) Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem. doi: 10.1016/j.jbc.2021.10077010.1016/j.jbc.2021.100770 Search in Google Scholar

23. Glaus MJ, Von Ruden S (2020) Remdesivir and COVID-19. The Lancet 396:952. doi: 10.1016/S0140-6736(20)32021-310.1016/S0140-6736(20)32021-3 Search in Google Scholar

24. Halford B (2021) PROCESS CHEMISTRY Chemists shorten synthesis of molnupiravir. Chem. Eng. News 99, 7–7. Search in Google Scholar

25. Hospital do Coracao (2020) Antiviral for Adult Patients Hospitalized for SARSCoV-2 Infection: a Randomized, Phase 2/3, Multicenter, Placebo Controlled, Adaptive, Multi-arm, Multi-stage Clinical Trial - Coalition Brazil COVID-19 IX: REVOLUTIOn (Clinical trial registration No. NCT04468087). clinicaltrials.gov. Search in Google Scholar

26. Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, Ng Y-Y, Lo J, Chan J, Tam AR, Shum H-P, Chan V, Wu AK-L, Sin K-M, Leung W-S, Law W-L, Lung DC, Sin S, Yeung P, Yip CC-Y, Zhang RR, Fung AY-F, Yan EY-W, Leung K-H, Ip JD, Chu AW-H, Chan W-M, Ng AC-K, Lee R, Fung K, Yeung A, Wu T-C, Chan JW-M, Yan W-W, Chan W-M, Chan JF-W, Lie AK-W, Tsang OT-Y, Cheng VC-C, Que T-L, Lau C-S, Chan K-H, To KK-W, Yuen K-Y (2020) Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet 395:1695–1704. doi: 10.1016/S0140-6736(20)31042-410.1016/S0140-6736(20)31042-4 Search in Google Scholar

27. Jomah S, Asdaq SMB, Al-Yamani MJ (2020) Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. J Infect Public Heal 13:1187–1195. doi: 10.1016/j.jiph.2020.07.01310.1016/j.jiph.2020.07.013 Search in Google Scholar

28. Jourdan J-P, Bureau R, Rochais C, Dallemagne P (2020) Drug repositioning: a brief overview. J Pharm Pharmacol 72:1145–1151. doi: 10.1111/jphp.1327310.1111/jphp.13273 Search in Google Scholar

29. Kaka AS, MacDonald R, Greer N, Vela K, Duan-Porter W, Obley A, Wilt TJ (2021) Major Update: Remdesivir for Adults With COVID-19 : A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points. Ann Intern Med. doi: 10.7326/M20-814810.7326/M20-8148 Search in Google Scholar

30. Kaur H, Shekhar N, Sharma S, Sarma P, Prakash A, Medhi B (2021) Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacol Rep. doi: 10.1007/s43440-020-00195-y10.1007/s43440-020-00195-y Search in Google Scholar

31. Kouznetsov VV (2020) COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus. Eur J Med Chem 203:112647. doi: 10.1016/j.ejmech.2020.11264710.1016/j.ejmech.2020.112647 Search in Google Scholar

32. Lai C-C, Chen C-H, Wang C-Y, Chen K-H, Wang Y-H, Hsueh P-R (2021) Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. J Antimicrob Chemother. doi: 10.1093/jac/dkab09310.1093/jac/dkab093 Search in Google Scholar

33. Lee N, Ison M, Dunning J (2020) Early triple antiviral therapy for COVID-19. The Lancet 396:1487–1488. doi: 10.1016/S0140-6736(20)32274-110.1016/S0140-6736(20)32274-1 Search in Google Scholar

34. Marcolino VA, Pimentel TC, Barão CE (2020) What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results. Eur J Pharmacol 887:173467. doi: 10.1016/j.ejphar.2020.17346710.1016/j.ejphar.2020.173467741441932777212 Search in Google Scholar

35. Mendieta Zerón H, Meneses Calderón J, Paniagua Coria L, Meneses Figueroa J, Vargas Contreras MJ, Vives Aceves HL, Carranza Salazar FM, Californias Hernández D, Miraflores Vidaurri E, Carrillo González A, Anaya Herrera J (2021) Nitazoxanide as an early treatment to reduce the intensity of COVID-19 outbreaks among health personnel. World Academy of Sciences Journal 3:1–6. doi: 10.3892/wasj.2021.9410.3892/wasj.2021.94 Search in Google Scholar

36. Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, Morin MJ, Szewczyk LJ, Painter GR (2021) Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2. Antimicrob Agents Chemother. doi: 10.1128/AAC.02428-2010.1128/AAC.02428-20809291533649113 Search in Google Scholar

37. Pani A, Lauriola M, Romandini A, Scaglione F (2020) Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. Int J Antimicrob Ag 56:106053. doi: 10.1016/j.ijantimicag.2020.10605310.1016/j.ijantimicag.2020.106053728625632534189 Search in Google Scholar

38. Pérez-Moraga R, Forés-Martos J, Suay-García B, Duval J-L, Falcó A, Climent J (2021) A COVID-19 Drug Repurposing Strategy through Quantitative Homological Similarities Using a Topological Data Analysis-Based Framework. Pharmaceutics 13:488. doi: 10.3390/pharmaceutics1304048810.3390/pharmaceutics13040488806615633918313 Search in Google Scholar

39. Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2 | pfpfizeruscom [WWW Document] (23 Mar 2021) https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-phase-1-study-novel-oral-antiviral Accessed 21 May 2021 Search in Google Scholar

40. Pfizer unveils its oral SARS-CoV-2 inhibitor [WWW Document] (07 Apr 2021) Chemical & Engineering News. https://cen.acs.org/acs-news/acs-meeting-news/Pfizer-unveils-oral-SARSCoV/99/i13 Accessed 21 May 2021 Search in Google Scholar

41. Pinho AC (2021) COVID-19 vaccines [WWW Document]. European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines Accessed 19 May 2021 Search in Google Scholar

42. Reina J (2021) [Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2]. Rev Esp Quimioter. doi: 10.37201/req/042.202110.37201/req/042.2021863883133902254 Search in Google Scholar

43. Repurposed Antiviral Drugs for Covid-19— Interim WHO Solidarity Trial Results (2021) New Engl J Med 384:497–511. doi: 10.1056/NEJMoa202318410.1056/NEJMoa2023184772732733264556 Search in Google Scholar

44. Richman DD (2020) Antiviral Drug Discovery To Address the COVID-19 Pandemic. mBio 11. doi: 10.1128/mBio.02134-2010.1128/mBio.02134-20752060032978312 Search in Google Scholar

45. Ridgeback Biotherapeutics, LP (2021) The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2 (Clinical trial registration No. NCT04405739). clinicaltrials.gov. Search in Google Scholar

46. Robinson J (19 Oct 2020) Antivirals have little effect on mortality in patients hospitalised with COVID-19, suggest WHO trial interim results [WWW Document]. The Pharmaceutical Journal. https://pharmaceutical-journal.com/article/news/antivirals-have-little-effect-on-mortality-in-patients-hospitalised-with-covid-19-suggest-who-trial-interim-results Accessed 30 Apr 2021 Search in Google Scholar

47. Rocco PRM, Silva PL, Cruz FF, Junior MACM, Tierno PFGMM, Moura MA, Oliveira LFGD, Lima CC, Santos EAD, Junior WF, Fernandes APSM, Franchini KG, Magri E, Moraes NF, de Gonçalves JMJ, Carbonieri MN, Santos ISD, Paes NF, Maciel PVM, Rocha RP, Carvalho AF, de Alves PA, Modena JLP, Cordeiro AT, Trivella DBB, Marques RE, Luiz RR, Pelosi P, Silva JRL (2020) Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial. Eur Respir J. doi: 10.1183/13993003.03725-202010.1183/13993003.03725-2020775877833361100 Search in Google Scholar

48. Sahakijpijarn S, Moon C, Koleng JJ, Christensen DJ, Williams RO (2020) Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing. Pharmaceutics 12:1002. doi: 10.3390/pharmaceutics1211100210.3390/pharmaceutics12111002769037733105618 Search in Google Scholar

49. Sahakijpijarn S, Moon C, Warnken ZN, Maier EY, DeVore JE, Christensen DJ, Koleng JJ, Williams RO (2021) In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters. International Journal of Pharmaceutics: X 3:100073. doi: 10.1016/j.ijpx.2021.10007310.1016/j.ijpx.2021.100073868366434977555 Search in Google Scholar

50. Salvi SS (2021) Is there a role for inhaled ciclesonide in the treatment of COVID-19? Lung India 38:1–4. doi: 10.4103/lungindia.lungindia_473_2010.4103/lungindia.lungindia_473_20806693933402630 Search in Google Scholar

51. SCCM | COVID-19 Guidelines [WWW Document] (29 Jan 2021) Society of Critical Care Medicine (SCCM). https://sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19 Accessed 12 May 2021 Search in Google Scholar

52. Şimşek Yavuz S, Ünal S (2020) Antiviral treatment of COVID-19. Turk J Med Sci 50:611–619. doi: 10.3906/sag-2004-14510.3906/sag-2004-145719597932293834 Search in Google Scholar

53. Solidarity clinical trial for COVID-19 treatments [WWW Document], n.d. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments Accessed 12 Dec 2020 Search in Google Scholar

54. Srinivas P, Sacha G, Koval C (2020) Antivirals for COVID-19. Clev Clin J Med. doi: 10.3949/ccjm.87a.ccc03010.3949/ccjm.87a.ccc03032409433 Search in Google Scholar

55. Taher M, Tik N, Susanti D (2021) Drugs intervention study in COVID-19 management. Drug Metab Pers Ther. doi: 10.1515/dmdi-2020-017310.1515/dmdi-2020-017333818031 Search in Google Scholar

56. Targeted Update: Safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19 [WWW Document] (17 Jun 2020) https://www.who.int/publications/m/item/targeted-update-safety-and-efficacy-ofhydroxychloroquine-or-chloroquine-for-treatment-of-covid-19 Accessed 13 Oct 2020 Search in Google Scholar

57. Teoh SL, Lim YH, Lai NM, Lee SWH (2020) Directly Acting Antivirals for COVID-19: Where Do We Stand? Front Microbiol 11. doi: 10.3389/fmicb.2020.0185710.3389/fmicb.2020.01857741965632849448 Search in Google Scholar

58. Wang J (2020) Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study. doi: 10.26434/chemrxiv.11875446.v110.26434/chemrxiv.11875446.v1 Search in Google Scholar

59. Xu J, Shi P-Y, Li H, Zhou J (2020) Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. ACS Infect Dis. doi: 10.1021/acsinfecdis.0c0005210.1021/acsinfecdis.0c00052709806932125140 Search in Google Scholar

60. Zhang Z, Wang S, Tu X, Peng X, Huang Y, Wang L, Ju W, Rao J, Li X, Zhu D, Sun H, Chen H (2020) A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID-19. J Med Virol 92:2631–2636. doi: 10.1002/jmv.2614110.1002/jmv.26141730066732501538 Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo